行情

AGTC

AGTC

应用基因科技公司
NASDAQ

实时行情|Nasdaq Last Sale

2.770
-0.100
-3.48%
盘后: 2.900 +0.13 +4.69% 17:58 11/15 EST
开盘
2.930
昨收
2.870
最高
2.990
最低
2.730
成交量
17.53万
成交额
--
52周最高
7.13
52周最低
2.260
市值
5,046.50万
市盈率(TTM)
-23.9619
分时
5日
1月
3月
1年
5年

分析师评级

6位分析师的综合评级

强力推荐

免责声明:分析师观点仅供投资者决策参考,不构成任何买卖投资建议。

EPS

AGTC 新闻

  • Applied Genetic Technologies Corporation (AGTC) CEO Sue Washer on Q1 2020 Results - Earnings Call Transcript
  • Seeking Alpha - Transcript.2天前
  • Edited Transcript of AGTC earnings conference call or presentation 12-Nov-19 9:30pm GMT
  • Thomson Reuters StreetEvents.2天前
  • Applied Genetic Technologies (AGTC) Reports Q1 Loss, Lags Revenue Estimates
  • Zacks.3天前
  • AGTC Announces Financial Results and Business Update for the Quarter Ended September 30, 2019
  • GlobeNewswire.3天前

更多

所属板块

生物技术和医学研究
+1.49%
制药与医学研究
+1.29%

热门股票

名称
价格
涨跌幅

AGTC 简况

Applied Genetic Technologies Corporation is a clinical-stage biotechnology company. The Company develops gene therapy products designed to manage the lives of patients with severe diseases in ophthalmology. As of March 31, 2016, its product candidates included treatments for X-linked retinoschisis (XLRS), over two forms of achromatopsia (ACHM) and X-linked retinitis pigmentosa (XLRP). As of March 31, 2016, the Company was engaged in developing three discovery programs, targeting three indications based on its adeno-associated virus vector technologies. XLRS is an inherited retinal degenerative disease caused by mutations in the retinoschisis1 (RS1) gene. Achromatopsia is an inherited condition that is associated with visual acuity loss, extreme light sensitivity resulting in daytime blindness, and reduced or complete loss of color discrimination, achromatopsia is caused by mutations in any of several genes. The Company is also developing Alpha-1 Antitrypsin Deficiency (Alpha 1).
展开

Webull提供Applied Genetic Technologies Corp的股票价格,实时市场报价,专业分析师评级,深度图表和免费的股票新闻,以帮助您做出投资决策。